Given the pronounced effect of HMGCS1 gene-silencing on CSC survival and seemingly mevalonate-pathway-independent regulation of HMGCS1, pharmacological inhibition of HMGCS1 may be a superior approach to specifically target CSC in luminal and basal breast cancer subtypes. Here, HMGCS1 is linked to breast carcinoma.